1. South Africa Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited

APN.JO
Aspen Pharmacare Holdings LimitedZA flagJohannesburg Stock Exchange
15,267.00
ZAc
-383.00
- -
67.79BMarket Cap
Aspen Pharmacare Holdings Limited
APN.JO
(Johannesburg Stock Exchange)

Recent

price

15,267.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
23.93
28.6
34.97
42.4
64.71
79.11
78
90.3
83.95
77.81
73.73
82.73
85.22
91.65
100.64
97.66
Revenue per Share
4.92
5.95
6.46
7.73
10.98
11.4
9.42
11.24
13.23
14.16
10.22
10.53
14.32
11.77
9.91
-2.44
Basic EPS, GAAP
1.84
3.71
0.66
-0.74
3.59
5.26
0.88
10.93
-2.65
5.3
18.09
14.95
11.86
12.43
14.01
11.62
Free Cash Flow per Basic Share
- -
0.7
1.05
1.57
1.57
1.97
2.19
2.7
2.88
3.15
- -
- -
2.64
3.28
3.43
3.61
Dividend per Share
26.92
30.35
10.78
8.76
50.51
60.49
66.83
73.47
84.17
94.95
105.15
115.76
124.41
135.41
141.33
135.38
Book Value per Share
4.13
-0.97
0.42
-4.63
-29.52
-24.98
-27.61
-51.61
-63.35
-37.04
-20.15
13.42
27.12
39.48
29.58
28.11
Tangible Book Value per Share
402
433
436
455
456
456
456
456
456
456
456
456
453
444
444
444
Basic Weighted Avg Shares
9,619
12,383
15,256
19,308
29,515
36,100
35,600
41,213
38,314
35,514
33,659
37,766
38,606
40,709
44,706
43,363
Sales/Revenue/Turnover
26.24
25.43
25.83
26.12
25.16
23.27
28.65
23.66
25.74
24.3
24.08
21.51
22.77
20.26
23.37
19.89
Operating Margin (%)
270
359
- -
- -
824
1,000
1,200
1,267
1,372
1,274
1,603
1,653
1,713
1,788
1,973
2,089
Depreciation Expense
1,978
2,578
2,818
3,520
5,008
5,200
4,300
5,128
6,037
6,463
4,664
4,806
6,488
5,228
4,404
-1,083
Net Income, GAAP
21.25
21.27
22.45
21.72
21.25
20
29.51
17.98
16.64
28.54
19.49
19.89
20.24
20.24
22.93
- -
Effective Tax Rate (%)
20.57
20.82
18.47
18.23
16.97
14.4
12.08
12.44
15.76
18.2
13.86
12.73
16.81
12.84
9.85
-2.5
Profit Margin (%)
1,793
1,166
3,112
2,912
15,171
10,900
16,100
2,557
11,293
16,113
18,659
-4,046
11,166
21,352
19,784
21,206
Working Capital
2,647
4,249
6,254
8,924
29,916
25,500
32,700
28,978
46,725
39,713
36,019
266
10,582
21,375
25,141
31,508
LT Debt
10,886
13,287
17,398
22,799
28,876
34,100
42,500
42,391
49,375
54,213
69,217
65,627
70,942
86,236
84,861
84,893
Total Equity
14.14
12.37
12.08
11.67
10.91
9.59
8.99
8.97
8.23
5.82
6.05
6.37
7.52
6.22
6.74
- -
Return on Invested Capital (%)
16.99
15.18
17.93
23.15
14.94
10.68
8.13
8.87
8.82
8.58
6.6
6.87
9.08
7.48
6.49
- -
Return on Capital (%)
26.45
21.52
31.58
80.99
37.06
20.54
14.8
16.02
16.78
15.81
10.21
9.53
11.88
8.97
7.16
-1.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.12%
4.58%
0.04%
Free Cash Flow
84.06%
-8.05%
-17.12%
Net Income, GAAP
-12.28%
-24.35%
-124.59%
Sales/Revenue/Turnover
2.15%
5.34%
-3%
Total Cash Common Dividend
- -
- -
4.98%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
44,706
2025
- -
- -
- -
- -
43,363
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
9.91
2025
- -
- -
- -
- -
-2.44
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3.43
2025
- -
- -
- -
- -
3.61
2026
- -
- -
- -
- -
- -
Similar Companies
Charlotte's Web Holdings, Inc. (CWEB.TO)
Biofrontera AG (B8FK.DE)
DMK Pharmaceuticals Corporation (0A4X.L)
Ascend Wellness Holdings, Inc. (AAWH)
Jupiter Wellness, Inc. (JUPW)
North Bud Farms Inc. (NOBDF)
Business
Aspen Pharmacare Holdings Limited is a multinational pharmaceutical company focused on manufacturing and marketing post-patent branded medicines and generics for hospital and consumer markets; its core products and services encompass injectable pharmaceuticals including anaesthetics, anticoagulants, antithrombotics, analgesics and hormone replacements, alongside prescription and over-the-counter medicines in forms such as steriles, oral solids, liquids, semi-solids, biologicals and active pharmaceutical ingredients. The company operates 24 manufacturing facilities across 15 sites in more than 48 countries and territories, serving patients in over 115 countries with approvals from regulators including the US FDA, Australian TGA and European Directorate for the Quality of Medicines. Founded in 1997 and headquartered in Durban, South Africa (uMhlanga), Aspen maintains a presence in emerging and developed markets across Africa, Europe, the Middle East, Asia Pacific, the Americas and Australasia through subsidiaries like Aspen Global Incorporated and Aspen Oss BV. Recent strategic developments include advancing its generic semaglutide GLP-1 programme for type 2 diabetes and obesity treatment with production onboarding at sterile facilities in South Africa and France, alongside regulatory progress on Serum Institute paediatric vaccines for African markets and a long-term distribution agreement with Boehringer Ingelheim for its South African portfolio effective September 2025. In 2024, Aspen secured a €500 million loan from IFC, Proparco, DEG and DFC to bolster vaccine, insulin and essential medicine production and distribution in Africa, while pursuing organic growth in commercial pharmaceuticals including Mounjaro Kwikpen approval in South Africa. The company continues targeted product pipeline development, reshapes its China business via the Sandoz acquisition and anticipates mid-single-digit revenue growth with stronger EBITDA in FY2026.